Researchers from McGill University reviewed 26 RCTs comprising 15,491 participants investigating 12 GLP-1 RAs and co-agonists for treating obesity in adults without diabetes. Twelve GLP-1 RA ...

but it is unknown how those outcomes compare with those of tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide RA. This retrospective cohort study aimed to investigate the ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Semaglutide (sold under the brand names Wegovy and Ozempic) and liraglutide (sold under the brand names Saxenda and Victoza) are glucagon-like peptide-1 receptor agonists, or GLP-1 RA medications.

and colleagues conducted a retrospective cohort study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA vs metformin and insulin. The study included ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.